Sidley acted as international counsel to lead managers Kotak Mahindra Capital Company Limited, ICICI Securities Limited, and J.P. Morgan India Private Limited in connection with the INR8.4 billion (approximately US$100 million) initial public offering (IPO) of India’s Blue Jet Healthcare Limited (Blue Jet).
Blue Jet is a specialty pharmaceutical and healthcare ingredients and intermediates company offering niche products targeted toward innovator pharmaceutical companies and multinational generic pharmaceutical companies.
The Sidley team was led by partner Manoj Bhargava and comprised counsel Shashwat Tewary and associate Edward Lee (all in Singapore) as well as partners Carla G. Teodoro, Nicholas R. Brown, and Robert M. Kreitman (all in New York) and managing associate Christian D. Barraza (Miami).
Sidley has had an active year advising India’s life sciences companies on their IPOs, including recently the US$185 million IPO of Concord Biotech and the US$530 million IPO of Mankind Pharma, India’s largest IPO in 2023.
